Trastuzumab biosimilar (Harbin Pharmaceutical Group)

曲妥珠单抗生物类似药（哈药集团）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTrastuzumab biosimilar (Harbin Pharmaceutical Group)
Drug Alias Name曲妥珠单抗生物仿制药（哈药集团）重组抗HER2人源化单抗（哈药集团）
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (IND)
Highest Status in ChinaPending
Originator CompaniesHarbin Pharmaceutical Group Holding Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHarbin Pharmaceutical Group Biological Engineering Co Ltd
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeL01XC03
Related LinksN/A